Why UroLift and Rezum Fail: Field Notes from the AUA 2026 BPH Failure Plenary
- Catherine Song, PhD.
- 15 hours ago
- 4 min read
Part two of my notes from the AUA 2026 plenary on BPH procedure failure. Part one covered the pattern that ran across all five technologies. This post goes deeper on UroLift and Rezum.
The same disclaimers apply. I am not a urologist. I was in the audience taking notes, and this is what I heard. For clinical depth and the underlying data, go to the panelists and the source literature.
UroLift
The UroLift panelist organized his entire talk around two root causes: poorly chosen patient, or properly chosen patient with improper technique. He said everything else flows from one of those two.
On selection: UroLift was originally approved for a specific anatomy. A prostate enlarged on both sides, no obstructing middle lobe, moderate size. When it gets used in a very large prostate, or one where the middle lobe is the dominant problem, you are asking the device to do something it was not built to do.
The case he walked through showed how that mismatch compounds. A patient had twelve UroLift implants placed without adequate imaging beforehand. That failed. A second urologist resected a small amount of tissue. Still no improvement. By the time the patient reached the panelist, an MRI showed a prostate far larger than anyone had assessed, with all twelve clips still in place. The fix was a robotic simple prostatectomy. His point: imaging before the procedure would have changed the entire decision tree from the start.
On technique: the failure he described was a device placed at the wrong angle. Too close to the bladder neck, so the needle entered the bladder itself rather than compressing the obstructing lobe. The patient had persistent storage symptoms that cystoscopy eventually explained. The panelist noted that surgeons are trained carefully on the correct instrument angulation, and that departing from it is where this pattern originates. His own habit: a pelvic X-ray in recovery after every UroLift case to confirm placement before the patient leaves.
When UroLift fails, his salvage approach follows prostate size. TURP for moderate glands, robotic simple prostatectomy for larger ones. He was direct that repeat minimally invasive intervention and medications have limited value at that point.
Rezum
The Rezum panelist opened with a reframe: failure is patient-defined, not just surgeon-defined. Someone who chose Rezum to preserve ejaculatory function has a different definition of failure than someone whose only goal was symptom relief. Different endpoints produce different numbers. Retreatment rates in the literature mean different things depending on which definition a study used.
His case: a man with a large prostate and a prominent middle lobe. The panelist described that anatomy as sitting at and arguably beyond the edge of where Rezum performs most reliably. The procedure was done, the initial course was typical, but at four months the patient still had significant obstructive symptoms. Cystoscopy showed the middle lobe had persisted, with what the panelist called intraprostatic cavitation. The tissue had changed, but not enough to open the channel.
The broader pattern he described: real-world practice has moved well beyond the original trial population. In carefully selected trial patients, retreatment rates were low. In larger glands, significant middle lobes, and catheter-dependent patients, rates rise. He was not saying Rezum should not be used in those populations. He was saying the failure patterns become more predictable, and the cystoscope usually shows exactly what happened.
On timing: most Rezum failures declare within the first year. If the patient is not clearly improving by three to six months, he said, that is the signal to investigate rather than reassure. Findings are typically anatomic. A persistent middle lobe. A high bladder neck. Asymmetric tissue response. His salvage principle: treat the anatomy you find, not the prior procedure. His case resolved with a targeted TURP of just the middle lobe. Ejaculatory function preserved.
The through-line for both
Both talks came back to the same point: pre-procedural assessment. Prostate volume, shape, and middle lobe anatomy determine whether either technology will do what it is supposed to do. Imaging before the procedure is what catches a mismatch before it becomes a failure.
The early follow-up window is where you find out whether the prediction was right. A patient not tracking toward improvement in the first few months is not a reason to wait longer. It is the signal to look.
That is where objective, repeatable measurement earns its place. Not as a replacement for cystoscopy, but as the early read that tells you whether a closer look is warranted. proudP gives clinicians and patients at-home flow measurement and a symptom record through the post-procedure window, so the question of whether someone is genuinely improving has an answer beyond how he felt at the last visit.
Part three covers HoLEP, TURP, and Aquablation.
Frequently asked questions
What is the most common reason UroLift fails?
Panelists at the AUA 2026 failure plenary described two root causes: poor patient selection and improper device placement. Poor selection usually means using UroLift in a very large gland or one where the middle lobe is the dominant obstruction. Both are largely preventable with pre-procedural imaging and careful instrument angulation.
When does Rezum tend to fail?
Most Rezum failures declare within the first year. Poor symptom improvement by three to six months is the cue to investigate. Common findings on cystoscopy include a persistent middle lobe and asymmetric or poorly positioned treatment areas.
Does prostate size matter for UroLift and Rezum outcomes?
Yes, significantly. Both panelists described failure patterns tied closely to using either technology outside the anatomy it was designed for. Pre-procedural imaging to assess volume and shape was the key preventive step both emphasized.